Trial · NCT02969928

Two Different Antibiotic Agents to Treat Generalized Aggressive Periodontitis

NCT02969928, Phase 2, Phase 3, Completed, Universidade Estadual Paulista Júlio de Mesquita Filho; results first posted 2020-09-07

3 sourcestrials-2026-11-12-0.5.0

Download JSON

Cite this record

ConductScience Library. Two Different Antibiotic Agents to Treat Generalized Aggressive Periodontitis. Trials, record NCT02969928. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02969928

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Two Different Antibiotic Agents to Treat Generalized Aggressive Periodontitis
NCT number: NCT02969928
Status: Completed
Phases: Phase 2, Phase 3
Enrollment: 46 participants, actual
Lead sponsor: Universidade Estadual Paulista Júlio de Mesquita Filho
Conditions: Aggressive Periodontitis
Interventions: Full-mouth ultrasonic debridement, Clarithromycin, Amoxicillin, Metronidazole
First posted: 2016-11-21
Last updated: 2021-12-28
Results first posted: 2020-09-07

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Clinical Attachment Level (CAL)	Baseline, 3 and 6 months	Evaluate the difference between baseline and 6 months CAL measures.
Secondary	Change in Probing Depth (PB)	Baseline, 3 and 6 months	Evaluate the difference between baseline and 6 months PB measures.
Secondary	Change in Bleeding on Probe (BoP)	Baseline, 3 and 6 months	Evaluate the difference between baseline and 6 months BoP measures.
Other	Compliance	One week post treatment	After 7 days of periodontal treatment, patients will be asked to return any medication not taken and/or the empty bottles. The number of pills not taken by the subject will be documented in order to evaluate compliance.
Other	Adverse Effects That May be Related to Antibiotic Treatment	One week post treatment	Patients will be instructed to fill a self-report form about any possible adverse effects in order to help evaluate their adherence to the systemic antimicrobial regimen.

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Change in Clinical Attachment Level (CAL)	Baseline, 3 and 6 months	mm	MEAN
SECONDARY	Change in Probing Depth (PB)	Baseline, 3 and 6 months	mm	MEAN
SECONDARY	Change in Bleeding on Probe (BoP)	Baseline, 3 and 6 months	% of sites with bleeding on probe	MEAN
OTHER_PRE_SPECIFIED	Compliance	One week post treatment	Participants	COUNT_OF_PARTICIPANTS
OTHER_PRE_SPECIFIED	Adverse Effects That May be Related to Antibiotic Treatment	One week post treatment	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group40

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Change in Clinical Attachment Level (CAL)	Amoxicillin and Metronidazole	Baseline	3.69	Standard Deviation 0.7	mm
Change in Clinical Attachment Level (CAL)	Clarithromycin	Baseline	3.62	Standard Deviation 0.4	mm
Change in Clinical Attachment Level (CAL)	Amoxicillin and Metronidazole	3 months	2.4	Standard Deviation 0.5	mm
Change in Clinical Attachment Level (CAL)	Clarithromycin	3 months	3	Standard Deviation 0.4	mm
Change in Clinical Attachment Level (CAL)	Amoxicillin and Metronidazole	6 months	3	Standard Deviation 0.5	mm
Change in Clinical Attachment Level (CAL)	Clarithromycin	6 months	3	Standard Deviation 0.4	mm
Change in Probing Depth (PB)	Amoxicillin and Metronidazole	Baseline	3.44	Standard Deviation 0.6	mm
Change in Probing Depth (PB)	Clarithromycin	Baseline	3.41	Standard Deviation 0.4	mm
Change in Probing Depth (PB)	Amoxicillin and Metronidazole	3 months	2.5	Standard Deviation 0.3	mm
Change in Probing Depth (PB)	Clarithromycin	3 months	2.7	Standard Deviation 0.2	mm

1 to 10 of 40Source ClinicalTrials.gov

See all 40 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Amoxicillin and Metronidazole	23
Overall Study	STARTED	Clarithromycin	23
Overall Study	COMPLETED	Amoxicillin and Metronidazole	23
Overall Study	COMPLETED	Clarithromycin	23
Overall Study	NOT COMPLETED	Amoxicillin and Metronidazole	0
Overall Study	NOT COMPLETED	Clarithromycin	0

Source ClinicalTrials.gov

Adverse events16

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Headache	General disorders	Amoxicillin and Metronidazole	1	23
other	Headache	General disorders	Clarithromycin	2	23
other	Stomach pain	Gastrointestinal disorders	Amoxicillin and Metronidazole	4	23
other	Stomach pain	Gastrointestinal disorders	Clarithromycin	3	23
other	Nausea/vomiting	General disorders	Amoxicillin and Metronidazole	3	23
other	Nausea/vomiting	General disorders	Clarithromycin	6	23
other	Metallic taste	General disorders	Amoxicillin and Metronidazole	7	23
other	Metallic taste	General disorders	Clarithromycin	13	23
other	Diarrhea/ abdominal pain	Gastrointestinal disorders	Amoxicillin and Metronidazole	3	23
other	Diarrhea/ abdominal pain	Gastrointestinal disorders	Clarithromycin	3	23

1 to 10 of 16Source ClinicalTrials.gov

See all 16 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Amoxicillin and Metronidazole	0	23
Total, all-cause mortality	Clarithromycin	0	23
Total, other adverse events	Amoxicillin and Metronidazole	18	23
Total, other adverse events	Clarithromycin	18	23
Total, serious adverse events	Amoxicillin and Metronidazole	0	23
Total, serious adverse events	Clarithromycin	0	23

Source ClinicalTrials.gov

Papers4

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
20447259	BACKGROUND	PubMed
21529775	BACKGROUND	PubMed
31257591	DERIVED	PubMed
33197289	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Amoxicillin and Metronidazole vs Clarithromycin: deaths from any cause	Trial comparisons
Amoxicillin and Metronidazole vs Clarithromycin: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02969928

GET https://conductscience.org/api/trials/v1/NCT02969928/results?page=2

API reference For AI assistants